401 related articles for article (PubMed ID: 27845387)
41. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
[TBL] [Abstract][Full Text] [Related]
42. Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells.
Tasca F; Brescia M; Wang Q; Liu J; Janssen JM; Szuhai K; Gonçalves MAFV
Nucleic Acids Res; 2022 Jul; 50(13):7761-7782. PubMed ID: 35776127
[TBL] [Abstract][Full Text] [Related]
43. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
Zhang Y; Bassel-Duby R; Olson EN
Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
[TBL] [Abstract][Full Text] [Related]
44. Selection-free precise gene repair using high-capacity adenovector delivery of advanced prime editing systems rescues dystrophin synthesis in DMD muscle cells.
Wang Q; Capelletti S; Liu J; Janssen JM; Gonçalves MAFV
Nucleic Acids Res; 2024 Mar; 52(5):2740-2757. PubMed ID: 38321963
[TBL] [Abstract][Full Text] [Related]
45. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
[TBL] [Abstract][Full Text] [Related]
46. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing.
Long C; Li H; Tiburcy M; Rodriguez-Caycedo C; Kyrychenko V; Zhou H; Zhang Y; Min YL; Shelton JM; Mammen PPA; Liaw NY; Zimmermann WH; Bassel-Duby R; Schneider JW; Olson EN
Sci Adv; 2018 Jan; 4(1):eaap9004. PubMed ID: 29404407
[TBL] [Abstract][Full Text] [Related]
47. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.
Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN
Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645
[TBL] [Abstract][Full Text] [Related]
48. Functional correction of dystrophin actin binding domain mutations by genome editing.
Kyrychenko V; Kyrychenko S; Tiburcy M; Shelton JM; Long C; Schneider JW; Zimmermann WH; Bassel-Duby R; Olson EN
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931764
[TBL] [Abstract][Full Text] [Related]
49. Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.
Pini V; Mariot V; Dumonceaux J; Counsell J; O'Neill HC; Farmer S; Conti F; Muntoni F
Sci Rep; 2022 Mar; 12(1):3756. PubMed ID: 35260651
[TBL] [Abstract][Full Text] [Related]
50. CRISPR Correction of Duchenne Muscular Dystrophy.
Min YL; Bassel-Duby R; Olson EN
Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
[TBL] [Abstract][Full Text] [Related]
51. CRISPR/Cas9-Based Dystrophin Restoration Reveals a Novel Role for Dystrophin in Bioenergetics and Stress Resistance of Muscle Progenitors.
Matre PR; Mu X; Wu J; Danila D; Hall MA; Kolonin MG; Darabi R; Huard J
Stem Cells; 2019 Dec; 37(12):1615-1628. PubMed ID: 31574188
[TBL] [Abstract][Full Text] [Related]
52. Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells.
Maggio I; Holkers M; Liu J; Janssen JM; Chen X; Gonçalves MA
Sci Rep; 2014 May; 4():5105. PubMed ID: 24870050
[TBL] [Abstract][Full Text] [Related]
53. Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model.
Bengtsson NE; Crudele JM; Klaiman JM; Halbert CL; Hauschka SD; Chamberlain JS
Mol Ther; 2022 Jun; 30(6):2176-2185. PubMed ID: 35143959
[TBL] [Abstract][Full Text] [Related]
54. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
[TBL] [Abstract][Full Text] [Related]
55. CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy.
Lim KRQ; Nguyen Q; Dzierlega K; Huang Y; Yokota T
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32213923
[TBL] [Abstract][Full Text] [Related]
56. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
[TBL] [Abstract][Full Text] [Related]
57. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy.
Amoasii L; Hildyard JCW; Li H; Sanchez-Ortiz E; Mireault A; Caballero D; Harron R; Stathopoulou TR; Massey C; Shelton JM; Bassel-Duby R; Piercy RJ; Olson EN
Science; 2018 Oct; 362(6410):86-91. PubMed ID: 30166439
[TBL] [Abstract][Full Text] [Related]
58. Exon Snipping in Duchenne Muscular Dystrophy.
Kemaladewi DU; Cohn RD
Trends Mol Med; 2016 Mar; 22(3):187-189. PubMed ID: 26856237
[TBL] [Abstract][Full Text] [Related]
59. Age-Dependent Echocardiographic and Pathologic Findings in a Rat Model with Duchenne Muscular Dystrophy Generated by CRISPR/Cas9 Genome Editing.
Sugihara H; Kimura K; Yamanouchi K; Teramoto N; Okano T; Daimon M; Morita H; Takenaka K; Shiga T; Tanihata J; Aoki Y; Inoue-Nagamura T; Yotsuyanagi H; Komuro I
Int Heart J; 2020 Nov; 61(6):1279-1284. PubMed ID: 33191355
[TBL] [Abstract][Full Text] [Related]
60. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells.
Gonçalves MA; Holkers M; Cudré-Mauroux C; van Nierop GP; Knaän-Shanzer S; van der Velde I; Valerio D; de Vries AA
Mol Ther; 2006 May; 13(5):976-86. PubMed ID: 16443396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]